Glauser, Tracy http://orcid.org/0000-0003-1520-2732
Becker, Danielle A. http://orcid.org/0000-0002-4792-8055
Long, Lucretia http://orcid.org/0000-0002-6240-3521
Detyniecki, Kamil http://orcid.org/0000-0002-8334-1403
Penovich, Patricia http://orcid.org/0000-0002-5831-8690
Sirven, Joseph http://orcid.org/0000-0001-9887-0917
Peters, Jurriaan M. http://orcid.org/0000-0002-6725-2814
Rabinowicz, Adrian L. http://orcid.org/0000-0003-1299-0606
Carrazana, Enrique http://orcid.org/0000-0001-8788-0722
Funding for this research was provided by:
Neurelis, Inc. (N/A)
Article History
Accepted: 10 June 2024
First Online: 28 June 2024
Declarations
:
: Dr Glauser is a consultant for Clarigent Health; BioMarin Pharmaceutical Inc.; and Neurelis, Inc. He receives research support from the National Institutes of Health. Dr Becker is a consultant/speaker for Neurelis, Inc.; SK Life Science, Inc.; and Jazz Pharmaceuticals; and received research support from SK Life Science, Inc. Dr Long is a consultant for Neurelis, Inc. and Catalyst Pharmaceuticals, Inc. She is on the advisory board of SK Life Science, Inc.; UCB, Inc.; and Neurelis, Inc.; and she is a speaker for Neurelis, Inc. Dr Detyniecki is a consultant for Aquestive; Neurelis, Inc.; UCB, Inc.; and Greenwich Biosciences. Dr Penovich has served on speakers bureaus for Jazz Pharmaceuticals; Neurelis, Inc.; SK Life Science, Inc.; and UCB, Inc.; and is a consultant to LVIS Corporation; Neurelis, Inc.; SK Life Science, Inc.; and UCB, Inc. Dr Sirven has served as a consultant for UCB Pharma; Acorda Therapeutics; Neurelis; and Upsher-Smith. Dr Peters has served as a speaker and consultant for Neurelis, Inc.; SK Life Science, Inc.; and Jazz Pharmaceuticals. Dr Rabinowicz is an employee of and has received stock options from Neurelis, Inc. Dr Carrazana is an employee of and has received stock and stock options from Neurelis, Inc.
: This article does not contain any studies with human or animal subjects performed by any of the authors.